A Global Real-World Evidence Study on the Effectiveness and Safety/Tolerability of Foslevodopa/Foscarbidopa in Patients Earlier Within Advanced Parkinson's Disease
Latest Information Update: 24 Feb 2026
At a glance
- Drugs Foscarbidopa/Foslevodopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms PUCCINI
- Sponsors AbbVie
Most Recent Events
- 17 Feb 2026 Planned initiation date changed from 24 Nov 2025 to 1 Mar 2026.
- 18 Nov 2025 New trial record